CanBas Co., Ltd. (JP:4575)
:4575
4575 Stock Chart & Stats
¥787.00
-¥23.00(-2.48%)
At close: 4:00 PM EST
¥787.00
-¥23.00(-2.48%)
Day’s Range― - ―
52-Week Range¥685.00 - ¥1,558.00
Previous CloseN/A
Volume347.00K
Average Volume (3M)268.48K
Market Cap
¥14.31B
Enterprise Value¥12.32B
Total Cash (Recent Filing)¥2.83B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,713,655
10 Day Avg. Volume208,910
30 Day Avg. Volume268,476
Financial Highlights & Ratios
PEG Ratio1.96
Price to Book (P/B)7.69
Price to Sales (P/S)0.00
P/FCF Ratio-29.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Debt And Materially Stronger EquityA debt-free balance sheet and a material equity infusion materially reduce near-term leverage risk and financing pressure. Over the next 2–6 months this improves runway flexibility, partner confidence for collaborations, and lowers mandatory interest or covenant constraints that can hamper R&D progress.
Partnership/licensing-driven Business ModelA business model focused on partnerships, licensing, and collaborative research lets the company de-risk development costs and monetize R&D via milestones and royalties. Structurally this reduces the need for full commercialization capital and aligns incentives with larger pharma partners.
Improving Cash-burn Trend In Latest YearA narrowing of operating and free cash burn signals improving operational efficiency or lower cash demands. If sustained, this trend lengthens runway and reduces near-term external funding dependence, making execution of planned development activities more viable over the medium term.
Bears Say
Persistent Operating And Net LossesThe company remains a pre-commercial biotech with recurring operating and net losses and essentially no product revenue. Over a multi-month horizon this maintains high execution and financing risk, as continued losses require external funding before any sustainable profitability can be achieved.
Negative Operating And Free Cash Flow Every YearChronic negative operating and free cash flow means the business cannot self-fund R&D and will likely need external capital or partner funding. This elevates dilution and financing execution risk and constrains the pace and scale of clinical programs over the next several quarters.
Negative Returns On Equity And Value ErosionA very negative ROE indicates that shareholder capital is being consumed rather than creating value. Structurally this questions capital efficiency and long-term investor returns until clinical success or licensing outcomes reverse value erosion.
4575 FAQ
What was CanBas Co., Ltd.’s price range in the past 12 months?
CanBas Co., Ltd. lowest stock price was ¥685.00 and its highest was ¥1558.00 in the past 12 months.
What is CanBas Co., Ltd.’s market cap?
CanBas Co., Ltd.’s market cap is ¥14.31B.
When is CanBas Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CanBas Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is CanBas Co., Ltd. overvalued?
According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued.
Does CanBas Co., Ltd. pay dividends?
CanBas Co., Ltd. does not currently pay dividends.
What is CanBas Co., Ltd.’s EPS estimate?
CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CanBas Co., Ltd. have?
CanBas Co., Ltd. has 19,713,655 shares outstanding.
What happened to CanBas Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CanBas Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CanBas Co., Ltd.
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―